Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
- 1 February 2006
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 57 (2), 145-164
- https://doi.org/10.1016/j.critrevonc.2005.06.007
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistanceProceedings of the National Academy of Sciences of the United States of America, 2005
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Approaches for the sequence-specific knockdown of mRNANature Biotechnology, 2003
- Mutations in the ABL kinase domain pre-exist the onset of imatinib treatmentSeminars in Hematology, 2003
- Molecular monitoring of chronic myeloid leukemiaSeminars in Hematology, 2003
- Molecular mechanisms of transformation by the BCR-ABL oncogeneSeminars in Hematology, 2003
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl Is Suppressed by Kinase-defective HckPublished by Elsevier BV ,2000
- Role of oxygen free radicals in cancer developmentEuropean Journal Of Cancer, 1996